A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Study of Olaparib in Combination with Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Sponsor: NIH
Enrolling: Female Patients Only
IRB Number: AAAS4040
U.S. Govt. ID: NCT03880019
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the good and bad effects of olaparib in combination with temozolomide for the treatment of advanced uterine leiomyosarcoma (LMS). Olaparib and temozolomide could shrink your cancer, but could also cause side effects, which are described in the risks section below. The study doctors hope to learn if the study drug will be a safe and effective treatment for people with this type of cancer.
This study is closed
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have advanced uterine leiomyosarcoma (LMS)? Yes No
Have you had prior progression on, or intolerance to, at least one line of systemic therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162